DNDi Symposium on ACT: 56th American Society of Tropical Medicine and Hygiene (ASTMH 2007)

[ November 2007 ]
Philadelphia, USA
Sanofi-aventis and DNDi held a symposium on the implementation of a new artemisinin combination therapy (ACT) in African endemic countries. Over 120 attendees from NGOs, academia, and the pharmaceutical sector heard presentations by FACT project partners on ASAQ and ASMQ. In addition, DNDi also presented the ethical considerations of malaria field studies, and screening of natural products against infectious disease pathogens.

Scientific Symposium on Visceral Leishmaniasis (VL)

[ September 2007 ]
London, UK
DNDi and the Leishmaniasis East Africa Platform (LEAP) organised a scientific symposium on visceral leishmaniasis (VL): “A step together in the right direction” at the centenary meeting of the Royal Society of Tropical Medicine and Hygiene (RSTMH), in London. More than 120 scientists attended the meeting.

ASAQ Launch

[ March 2007 ]
Sanofi-aventis and DNDi launched ASAQ, the new fixed-dose combination of artesunate (AS) and amodiaquine (AQ), which is now available in 21 countries throughout sub-Saharan Africa (June 08). ASAQ, the first drug developed by DNDi, is an innovative product to treat malaria that is adapted to the needs of patients of all ages, simple to use, accessible as a non patented drug, and available at an affordable price.